SCHEMBL2329778

SCHEMBL2329778

CCOC(COc1ccc(Br)cc1)OCC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.46
TDP1 Q9NUW8 2/20 0.46
MAPK1 P28482 2/20 0.46
MAPT P10636 2/20 0.45
NQO1 P15559 1/20 0.43
ALDH1A1 P00352 4/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
HTT P42858 1/20 0.42
PPARG P37231 1/20 0.39
PPARD Q03181 1/20 0.39
PPARA Q07869 1/20 0.39
MAOB P27338 1/20 0.39
APP P05067 1/20 0.38
USP2 O75604 1/20 0.38
TSHR P16473 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicarbonate SCHEMBL18990211 0.89 KDM4E (0.45) KDM4ETDP1MAPK1MAPTALDH1A1
Bicarbonate SCHEMBL18990209 0.89 KDM4E (0.45) KDM4ETDP1MAPK1MAPTALDH1A1
SCHEMBL17400969 0.86 NQO1 (0.61) KDM4ETDP1MAPTNQO1ALDH1A1
SCHEMBL4027763 0.84 NPSR1 (0.48) KDM4ETDP1MAPK1MAPTALDH1A1
SCHEMBL16519363 0.84 NQO1 (0.46) KDM4ETDP1MAPTNQO1ALDH1A1
SCHEMBL12261462 0.83 MAPT (0.47) KDM4ETDP1MAPK1MAPTNQO1
SCHEMBL5779539 0.82 USP2 (0.45) KDM4EMAPTNQO1SMN1; SMN2MEN1
SCHEMBL1951190 0.82 CYP2C9 (0.50) KDM4EMAPK1MAPTNQO1ALDH1A1
SCHEMBL7362624 0.81 NQO1 (0.40) KDM4ETDP1MAPK1NQO1MEN1
SCHEMBL2329756 0.81 CYP1A2 (0.47) TDP1NQO1MEN1KMT2AMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0357348-B1 Process for preparing p-bromophenoxyacetaldehyde dialkylacetal derivatives UBE INDUSTRIES (JP) 1994-06-08 EP claimed
EP-0357348-A2 Process for preparing p-bromophenoxyacetaldehyde dialkylacetal derivatives UBE INDUSTRIES, LTD. (JP) 1990-03-07 EP claimed
EP-4600247-A2 PD-1/PD-L1 INHIBITORS Gilead Sciences, Inc. (US) 2025-08-13 EP disclosed
EP-3781556-B1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES INC (US) 2025-06-18 EP disclosed
US-20240360082-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2024-10-31 US disclosed
EP-3978472-B1 BIARYL MONABACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS MERCK SHARP & DOHME LLC (US) 2024-10-16 EP disclosed
CN-108368040-B Diaryl monocyclic beta-lactam compounds and methods for their use in the treatment of bacterial infections 默沙东有限责任公司 2024-08-23 CN disclosed
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 EP disclosed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN disclosed
CN-112041311-B PD-1/PD-L1 inhibitors 吉利德科学公司 2023-10-03 CN disclosed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO disclosed
US-7338968-B2 Thiadiazoles AS CXC- and CC- chemokine receptor ligands SCHERING CORPORATION (US) 2008-03-04 US disclosed
US-20070264230-A1 Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands SCHERING CORPORATION 2007-11-15 US disclosed
US-20070264230-A1 Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands SCHERING CORPORATION 2007-11-15 US disclosed
EP-1818325-A2 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands SCHERING CORPORATION (US) 2007-08-15 EP disclosed
US-20070021494-A1 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands SCHERING CORPORATION AND PHARMACOPEIA, INC. 2007-01-25 US disclosed
US-20070021494-A1 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands SCHERING CORPORATION AND PHARMACOPEIA, INC. 2007-01-25 US disclosed
EP-0357348-B1 Process for preparing p-bromophenoxyacetaldehyde dialkylacetal derivatives UBE INDUSTRIES (JP) 1994-06-08 EP disclosed
US-4982008-A Process for preparing p-bromophenoxyacetaldehyde dialkylacetal compounds UBE INDUSTRIES, LTD. (JP) 1991-01-01 US disclosed
EP-0357348-A2 Process for preparing p-bromophenoxyacetaldehyde dialkylacetal derivatives UBE INDUSTRIES, LTD. (JP) 1990-03-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021494-A1 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands CCR1, ACKR3, CXCR1 KDM4E 4760/4885TDP1 4014/4885MAPK1 661/4885
US-20070264230-A1 Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands CXCR1, CCR2, CX3CR1 KDM4E 4781/4885TDP1 3710/4885MAPK1 1382/4885
US-20240360082-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS PNPO, PDXK, PLPBP KDM4E 1906/4885TDP1 725/4885MAPK1 773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.